Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | BHMT | Q93088 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | EYA2 | O00167 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25129557 | 0.98 | MVD (0.37) | MVDGBA1CA14PDK2BHMT | |
| SCHEMBL19865535 | 0.85 | GBA1 (0.35) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL10260946 | 0.84 | HDAC6 (0.40) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL336495 | 0.83 | HDAC6 (0.37) | MVDGBA1CA14PDK2HDAC6 | |
| SCHEMBL18257000 | 0.81 | CA14 (0.42) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL21871862 | 0.81 | GBA1 (0.35) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL25479216 | 0.81 | CA14 (0.42) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL7783463 | 0.81 | HDAC6 (0.38) | GBA1CA14PDK2HDAC6HDAC1 | |
| SCHEMBL20762898 | 0.81 | GBA1 (0.39) | GBA1CA14PDK2HDAC6HDAC1 | |
| Ammonia Solution, Strong SCHEMBL29062672 | 0.81 | HDAC6 (0.36) | MVDGBA1CA14PDK2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| CN-1964979-B | Novel water-soluble prodrug | CHUGAI PHARMACEUTICAL CO LTD | 2011-07-27 | — | — | CN | disclosed |
| CN-101291675-B | Novel anticancer concomitant drug | CHUGAI PHARMACEUTICAL CO LTD | 2011-04-13 | — | — | CN | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| CN-1964979-A | Novel water-soluble prodrug | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-05-16 | — | — | CN | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | MVD 4073/4885GBA1 460/4885CA14 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.